throbber
vt’~ RIGI NAL RESEARCH ARTICLE
`
`Am J Clin D .... to1201 l;l 2 (2):I 33 141
`1175 0561/11/0002 0133/$49.95/0
`
`© 2011 Adis Data Information BV. All rights reserved.
`
`Resveratrol-Containing Gel for the
`Treatment of Acne Vulgaris
`A Single-Blind, Vehicle-Controlled, Pilot Study
`
`Gabriella Fabbrocini, Stefania Staibano, Giuseppe De Rosa, Valeria Battimiello, Nunzio Fardella, Gennaro Ilardi,
`Maria Immacolata La Rotonda, Amelia Longobardi, Marialuisa Mazzella, Maria Siano, Francesco Pastore,
`Valerio De Vita, Maria Luisa Vecchione and Fabio Ayala
`
`Department of Systematic Pathology, Division of Clinical Dermatology, University of Naples Federico II, Naples, Italy
`
`Abstract
`
`Background: Acne vulgaris is a complex, chronic, and common skin disorder of pilosebaceous units. The
`major pathogenic factors involved are ductal hyperkeratinization, obstruction of sebaceous follicles re-
`sulting from abnormal keratinization of the infundibular epithelium, stimulation of sebaceous gland se-
`cretion by androgens, and microbial colonization of pilosebaceous units by Propionibacterium aches, which
`promotes perifollicular inflammation.
`Aim: The aim of the study was to investigate the therapeutic effects of resveratrol, a natural phytoalexin
`produced by some spermatophytes, such as grapes and other plants, on acneic skin.
`Methods: Resveratrol was incorporated in a carboxymethylcellulose-based gel. The chemical stability of
`resveratrol after storage at 4°C for 30 days was investigated by high-performance liquid chromatography
`(HPLC). The resveratrol-containing hydrogel was administered to 20 patients affected by acne vulgaris
`enrolled in this single-blind study. The resveratrol-containing formulation was applied daily as a solo
`treatment on the right side of the face for 60 days, while the hydrogel vehicle was applied to the left side of the
`face as a control. To objectively evaluate the results, a digital photographic database was used to collect
`images. The number and type of lesions were recorded for each patient, to compare the Global Acne Grading
`System (GAGS) score before treatment with that obtained at the end of the study. Moreover, with the
`innovative technique of follicular biopsy, areas of acneic skin were prepared for histopathology. The average
`area occupied by microcomedones at baseline was compared with that at the end of treatment.
`Results: HPLC analysis demonstrated that resveratrol, upon incorporation into the gel, did not convert to its
`cis-isomer when stored at 4°C for 30 days. All patients were satisfied with the active treatment and none
`experienced adverse effects. Clinical evaluation showed a 53.75% mean reduction in the GAGS score on the
`resveratrol-treated sides of the face compared with 6.10% on the vehicle-treated sides of the face. These data
`were supported by histologic analysis, which showed a 66.7% mean reduction in the average area of micro-
`comedones on the resveratrol-treated sides of the face. The comparison with the vehicle-treated side of
`the face (9.7% reduction) showed a clinically relevant and statistically significant decrease of lesions in areas
`treated with resveratrol-containing hydrogel.
`Conclusion: This pilot study showed positive results for resveratrol gel in acne, and should be considered a
`valid starting point for further testing of the effectiveness of this molecule in different concentrations and
`formulations and in a larger group of patients.
`
`Background
`
`Ache vulgaris is a complex, chronic, and common skin dis-
`order of pilosebaceous units that occurs predominantly on the
`skin of the face, the upper back, and the upper chest. This
`
`disease usually begins at the time of the sharp increase in an-
`drogen production that occurs during adolescence, but may
`affect individuals of any age.Ill In recent years, the multi-
`factorial nature of ache has been elucidated but much remains
`to be learned. The major pathogenic factors involved are ductal
`
`1 of 9
`
`Almirall EXHIBIT 2032
`Amneal v. Almirall
`IPR2018-00608
`
`

`

`134
`
`Fabbrocini et al.
`
`Recently, it has been demonstrated that, in inflammatory
`hyperkeratinization, obstruction of sebaceous follicles resulting
`acne lesions, there is activation of nuclear factor-KB signaling
`from abnormal keratinization of the infundibular epithelium,
`(a transcription factor critical for upregulation of many proin-
`stimulation of sebaceous gland secretion by androgens, and
`flammatory cytokine genes). As a result, inflammatory cyto-
`microbial colonization of pilosebaceous units by Propioni-
`kine genes (e.g. tumor necrosis factor [TNF]-~ and interleukin
`bacterium aches, which promotes perifollicular inflammation,
`[IL]-IB) are activated. These primary cytokines cause in-
`Acne begins when the pilosebaceous ducts become plugged
`flammation by acting on endothelial cells to prepare adhesion
`with keratinocytes to form comedones, sebum builds up and
`distends the follicles, and the anerobe P. aches proliferates molecules (e.g. intercellular adhesion molecule-l) to facilitate
`in the sebum. If the comedo ruptures into the dermis, in-
`recruitment of all inflammatory cells into the skin. TNF~ and
`flammation results and a pustule or papule forms.[2]
`IL-1B also help to stimulate the proliferation of secondary
`Currently, inflammatory acne is treated with antibacterials
`cytokines, such as IL-8, which can cooperate in the movement
`(both oral and topical) or oral isotretinoin. Although widely
`of the inflammatory cells towards the increased concentration
`of these particular chemicals.[12]
`used and often effective, antibacterials have a significant limi-
`ration, which is the development of resistant strains of P. aches.
`P. aches seems to be involved in both the initiation of acne
`lesions as a precursor of inflammation and in later events.
`Oral isotretinoin is by far the most effective treatment for severe
`P. aches is a Gram-positive, non-motile rod, non-spore-
`inflammatory acne, routinely delivering dramatic improve-
`ments.[3-6] However, because of its established teratogenicity,
`forming, anerobic bacillus. As it is a member of the normal
`isotretinoin use has been restricted. Furthermore, the recently
`flora and is a harmless commensal, it is largely incapable of
`publicized, controversial risk of depression/suicidal ideation
`tissue invasion or serious infection. The organism metabolizes
`has made isotretinoin use even more problematic.[7,8] Current
`sebaceous triglycerides, consuming the glycerol fraction and
`topical treatment options for inflammatory acne are sub-
`discarding free fatty acids. As a consequence of P. aches proli-
`optimal. Rational development of new treatments for acne is
`feration and metabolism in the obstructed follicles, P. aches pro-
`based on a molecular description of the mechanisms involved
`duces neutrophil chemoattractants. P. aches also activates the
`complement system and is generally inflammatory when brought
`in acne.
`into contact with the immune system.[13] It has been shown that
`Overstimulation of the initiation of the preclinical in-
`flammatory process or defective negative feedback regulation
`P. aches, through activation of toll-like receptor 2 expressed in
`may be major reasons for the interruption of the normal cycling
`human monocytes, induces chemokine/cytokine synthesis in
`these cells.[14] These findings in combination with the expression
`of the sebaceous follicle and be responsible for the initiation of
`the clinical inflammatory process in acne. Hereditary factors
`of active toll-like receptors 2 and 4 and of CD 14 in human ker-
`and excess androgen activity, for example, in puberty, may
`atinocytes have implicated P. aches and toll-like receptors in acne
`cause overstimulation, thus triggering sterile inflammatory
`inflammation. Recently, it has been shown that keratinocytes
`phenomena. Neuroendocrinologic regulation and environ-
`secrete selective human [3-defensin-2 (hBD2) and IL-8 in res-
`mental factors, such as dietary lipids and smoking, have also
`ponse to P. aches and that these molecules are potent chemo-
`been suggested to represent trigger mechanisms.[9] Hyper-
`tactic factors for leukocyte and neutrophil infiltration as well as
`proliferation of the follicular epithelium leads to formation of
`for keratinocyte growth potential and differentiation at the site
`the first acne lesions that can be found in normal-looking skin,
`of P. aches infections. This evidence shows that P. aches is im-
`portant for maintaining the inflammation process in acne.[ls]
`the microcomedones (comedones with an area between 0.016
`and 0.042mm2), characterized by the accumulation of abnor-
`Because of the pathophysiology of the disease, the ideal
`mally desquamated corneocytes and excess sebum[1°] and which
`treatment would be a single drug capable of suppressing the
`are believed to be the precursor lesions of acne. The micro-
`inflammatory response and also inhibiting keratinocytes and
`comedones may evolve into clinically visible comedones
`P. aches proliferation. A potential candidate to fulfill these
`(blackheads and whiteheads)or inflammatory lesions (papules,
`criteria is the phytoalexin resveratrol (3,4,5-trihydroxy-trans-
`pustules, or cysts). The very early stage of acne lesion devel-
`stilbene). Resveratrol is a natural compound that exists in
`opment is associated with vascular endothelial cell activation
`nature as cis- and trans-isomers. Most of the recorded health
`and involvement of inflammatory events,[111 which corrobo-
`benefits are attributed to the trans-isomer.[161 The aim of this
`rates the suggestion that acne may represent a genuine in-
`pilot cosmetic study was to evaluate the effects of a new topical
`flammatory disorder without involvement of bacteria in its
`formulation of trans-resveratrol in patients affected by in-
`flammatory acne vulgaris.
`initiation,
`
`© 2011 Adis Data Information BV All rights reserved
`
`Am J Clin Dermato12011; 12 (2)
`
`2 of 9
`
`

`

`Resveratrol-Containing Gel for Acne Vulgaris
`
`135
`
`stirring in the absence of light. The vehicle gel and resveratrol-
`containing gel were stored at 4°C.
`The stability of trans-resveratrol in the gel was evaluated
`soon after preparation and after different time frames of stor-
`age at 4°C. For each analysis, 0.5 g of the preparation was taken
`from the sample and resveratrol was extracted with 5mL of
`methanol; then, the suspension was centrifuged at 4°C for
`30 minutes at 60 x g and the supernatant was analyzed by HPLC.
`
`Materials and Methods
`
`Patients
`
`The study group consisted of 20 patients (12 men and
`8 women) with facial acne vulgaris involving both sides of their
`faces with nearly symmetric appearance, as determined by
`clinical criteria. Their age at entry to the trial ranged from 18 to
`23 years.
`At the time the study started, patients had been in ther-
`apeutic wash-out for at least 4 weeks for both topical and sys-
`temic acne therapies. The exclusion criteria were a history of
`allergy, diabetes mellitus, and severe systemic disease.
`
`Materials
`
`Trans-resveratrol, sodium carboxymethylcellulose, and
`polysorbate 60 were purchased from Sigma-Aldrich Corp.
`(St Louis, MO, USA). Analytic grade 96% ethanol, and high-
`performance liquid chromatography (HPLC) grade acetoni-
`trile, methanol, and glacial acetic acid were obtained from
`Carlo Erba Reagenti (Milan, Italy). Glycerol (glycerin) was
`purchased from Polichimica (Bologna, Italy).
`
`Methods
`
`Cyanoacrylate Follicular Biopsy
`Cyanoacrylate follicular biopsy, also known as skin surface
`biopsy, is a simple noninvasive method that removes only dead
`tissue and is used to study the stratum corneum, the many types
`of pathology within this compartment, and a vast array of
`microorganisms that may colonize or invade the layer.[17]
`It is the most reliable tool to sample the follicular contents of
`facial skin[18] such as hair and keratin. In the acneic or nearly
`acneic skin, keratin material may be particularly abundant
`(microcomedones) prior to the appearance of clinically evident
`comedones (macrocomedones). Cyanoacrylate follicular bi-
`opsy was performed by distributing three drops of cyanoacry-
`late evenly on a slide holder, which was then applied with a
`slight pressure to the chosen area of the face. After about
`3 minutes, the slide was removed, stripping an area of skin
`surface with a slow and undulating movement and being careful
`Resveratrol Analysis
`not to damage the stratum corneum sticker with its comedones.
`Ematossilin-eosin was used to stain each sample and the
`Trans-resveratrol analysis and detection of cis-resveratrol
`were carried out using an HPLC system by Shimadzu (Kyoto, micrometric scale of the Zeiss optical microscope was used to
`determine the density of microcomedones, i.e. the number
`Japan), consisting of a LC-10AD pump equipped with a Luna
`present per mm:, and the area occupied by each micro-
`C18 (250x4.6mm, 5rim) column (Phenomenex, Torrance,
`CA, USA), a Rheodyne 7725i injection valve, and a SPV-10A
`comedone. From these calculations, we then determined the
`average area of microcomedones. The parameter used to test
`UV-vis detector set at the wavelength of 303 nm. The system
`the treatment was the average area occupied by micro-
`was controlled by a SCL-10A VP System Controller (Shi-
`comedones before and after treatment.
`madzu) connected with a computer. Chromatograms were ac-
`quired and analyzed by a Class VP Client/Server 7.2.1 program
`(Shimadzu). The analysis was performed with a mobile phase of
`methanol/water (50 : 50) with 0.5% volume in volume acetic
`acid in isocratic conditions at a flow rate of 1 mL/min. Cis-
`resveratrol was prepared from the trans-isomer by sunlight
`irradiation for 3 days, as reported elsewhere.[16]
`
`Preparation of the Resveratrol-Containing Gel
`The gel was prepared by dissolving 5 g of sodium carboxy-
`methylcellulose and 10 g of 85% glycerol in 85 g of deionized
`water under stirring. Separately, in the absence of light, res-
`veratrol was dissolved in deionized water at a final concen-
`tration of 0.01% weight in volume. Then, 1 g of this aqueous
`solution was incorporated into 10 g of the vehicle gel under
`
`Resveratrol Protocol and Patient Monitoring
`At baseline (To), patients underwent a careful dermatologic
`examination and received accurate information about the stu-
`dy. All patients signed the informed consent, which contained
`the study’s description, aims, methods, and possible adverse
`effects. The study was submitted to a cosmeceutic committee,
`according to Italian cosmeceutic rules.
`In order to carry out a comparative analysis, three digital
`photographs (front view, right side of the face, left side of the
`face) were taken and gathered in a database. The severity of the
`lesions was evaluated using the Global Acne Grading System
`(GAGS)[191 that considers six sites (five facial, one truncal) by
`giving each a specific numerical factor based on the surface area
`
`© 2011 Adis Data Information BV All rights reserved
`
`Am J Olin Dermato12011; 12 (2)
`
`3 of 9
`
`

`

`136
`
`Fabbrocini et al.
`
`Table I. Global Acne Grading System (GAGS)
`
`SfQfisficQI AnQlysis
`
`Localization Factor per grade (0-4) Grade
`
`I = forehead 2 xgrade 0 = no lesions
`
`II = right cheek
`
`III = left cheek
`
`IV = nose
`
`V=chin
`
`Vl = chest and back
`
`2 xgrade
`2 x grade
`1 x grade
`
`1 xgrade
`
`3 x grade
`
`1 =>1 comedo
`2 =_>1 papule
`3 =_>1 pustule
`
`4=_>1 nodule
`
`The digital photographic data were analyzed using a test for
`nonparametric data (Wilcoxon signed-rank test for paired data).
`The null hypothesis (H0) was that the median of the differences is
`zero (P+ = P-) and the alternative hypothesis (HA) was that the
`median of the differences is negative (P+ < P-), c~ = 0.001. The
`result is given by computing the binomial probability.
`
`Results
`
`1500
`e0 1000
`>
`E 5oo
`
`0
`
`0
`
`2
`
`6
`4
`Time (rain)
`
`8
`
`10
`
`of each and the distribution and density of pilosebaceous units.
`This factor is multiplied by the known grade to give the value of
`The first step of the study was the development of an HPLC
`the local score. The sum of the local scores gives the global score method to allow the detection of both trans- and cis-isomers of
`resveratrol. The chromatographic analysis of the aqueous sol-
`(table I).
`At the end of the study, patients were asked to rate the clinical
`ution containing trans-resveratrol gave a well defined peak with
`results on a 10-point satisfaction scale (1 = lowest to 10 = highest)
`the retention time of 6.4 minutes. The sunlight irradiation of the
`including compliance, smell, texture, results, and quality of life.
`trans-resveratrol solution for 3 days resulted in two distinct
`chromatographic peaks that were attributed, based on a pre-
`Before the treatment was started, the GAGS score was cal-
`culated and all patients with a score between 8 and 24 were
`vious report,I2°1 to trans- and cis-resveratrol, respectively (data
`included in the study. In order to obtain an objective evaluation
`not shown).
`of the efficacy of the treatment, the number of acne lesions
`The second step of the study was the preparation of a der-
`before beginning treatment and at the end of the study was matologic formulation containing resveratrol in which trans-
`recorded for each patient,
`resveratrol was incorporated at the final concentration of 1 gg/g
`Moreover, to better define clinical results and to correctly
`of preparation. The stability of resveratrol in the preparation
`evaluate the efficacy ofthe therapy, for each patient, twocyano- was evaluated soon after preparation and after 1, 10, and
`acrylate follicular biopsies (on the right and left sides of the face)
`30 days of storage at 4°C by HPLC analysis. Figure 1 shows the
`were executed. Furthermore, digital photographs were captured
`chromatogram obtained from the analysis of the resveratrol-
`while performing cyanoacrylate follicular biopsies: this guar-
`containing gel after 30 days of storage. In this figure, only the
`anteed the reproducibility of the technique and better diagnostic
`chromatographic peak attributed to trans-resveratrol was ob-
`accuracy,
`served, while there were no peaks at a higher retention time, in-
`The study was single blinded; each patient received two
`dicatingthe absence ofcis-resveratrol. The chromatographicpeaks
`identical containers, marked by a letter of reference: ’C’ for the with a retention time between 2 and 4 minutes (figure 1) were
`formulation containing the vehicle gel and ’R’ for the medi-
`not attributed to resveratrol or to chemical compounds derived
`cared formulation. Each patient was instructed to apply the gel
`from it, because they were also found upon analysis of the vehi-
`in container R to the right side of the face, and the gel in con-
`cle gel.
`tainer C to the left side once a day, preferably in the evening.
`It is noteworthy that, in this study, in order to avoid inter-
`Patients were told to store the gels in the refrigerator at a stable
`ference with resveratrol activity on the skin, preservatives were
`temperature.
`All patients attended the first follow-up visit 1 month later
`(T1) and each had three digital photographs taken. By analyz-
`ing digital photographs collected at To, two follicular biopsies
`were obtained from the same sites of each patient’s face. Each
`patient returned the questionnaire that was given out during the
`first visit and since no patient had adverse effects, treatment was
`continued and the patients were asked to return for the last
`control check after a further 30 days.
`Therefore, the second and final follow-up occurred 60 days
`(T2) after the baseline visit, with the same evaluations repeated,
`
`Fig. 1. Chromatogram from the analysis of the resveratrol-containing gel
`after storage at 4°C for 30 days.
`
`© 2011 Adis Data Information BV All rights reserved
`
`Am J Olin Dermato12011; 12 (2)
`
`4 of 9
`
`

`

`Resveratrol-Containing Gel for Acne Vulgaris
`
`137
`
`Table II. Global Acne Grading System (GAGS) score before and alter tre~ment with resveratrol and vehicle gels
`
`P~ient no.
`
`Resver~rol-tre~ed side
`
`Vehicle-tre~ed side
`
`GAGS score before
`tre~ment
`
`GAGS score after
`tre~ment
`
`redu~ion
`(%)
`
`GAGS score before
`tre~ment
`
`GAGS score after
`tre~ment
`
`reduction
`(%)
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`14
`
`12
`
`33
`
`14
`
`16
`
`9
`
`22
`
`14
`
`15
`
`18
`
`7
`
`2
`
`8
`
`10
`
`12
`
`6
`
`12
`
`7
`
`3
`
`5
`
`50
`
`83
`
`76
`
`29
`
`25
`
`33
`
`45
`
`50
`
`80
`
`72
`
`14
`
`12
`
`33
`
`14
`
`16
`
`9
`
`22
`
`14
`
`15
`
`18
`
`12
`
`12
`
`28
`
`18
`
`14
`
`15
`
`16
`
`12
`
`11
`
`16
`
`15
`
`14
`
`0
`
`15
`
`-28
`
`12
`
`-67
`
`27
`
`14
`
`27
`
`11
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`16
`
`26
`
`15
`
`19
`
`29
`
`23
`
`17
`
`18
`
`16
`
`22
`
`4
`
`7
`
`6
`
`8
`
`15
`
`16
`
`10
`
`11
`
`9
`
`8
`
`75
`
`73
`
`60
`
`58
`
`48
`
`30
`
`41
`
`39
`
`44
`
`64
`
`16
`
`26
`
`15
`
`19
`
`29
`
`23
`
`17
`
`18
`
`16
`
`22
`
`24
`
`14
`
`18
`
`28
`
`22
`
`17
`
`17
`
`15
`
`21
`
`6
`
`8
`
`7
`
`5
`
`3
`
`4
`
`0
`
`5
`
`6
`
`5
`
`Mean
`
`18.40
`
`8.30
`
`53.75
`
`18.40
`
`17.25
`
`6.10
`
`crease in the density of microcomedones (area between 0.016
`not added. Indeed, for time frames longer than 1 month, the
`presence of microbiologic contamination was sometimes ob-
`and 0.042mm:) on the resveratrol-treated side of the face,
`served. For this reason, although resveratrol transformation
`versus a 9.7% decrease on the vehicle-treated side of the face
`(table III). Furthermore, there was a total disappearance of
`was not observed at the timepoints considered, the resveratrol-
`containing formulations were used for no more than 30 days, macrocomedones in some patients (figures 4 and 5).
`after which time new preparations were provided to the patients.
`According to the patients’ subjective self-evaluation, using
`Data obtained using the GAGS at To, T1, and T: showed an
`the 10-point scale, the mean satisfaction rate was 8 for com-
`average 53.75% reduction in clinical lesions on the resveratrol-
`pliance, 9 for smell, 8 for texture, 8 for results, and 9 for quality of
`treated sides of the face compared with 6.10% on the vehicle-
`life.
`treated sides of the face (table II).
`Data collected from digital photographs at times To, T1, and
`T: and analyzed with the sign test for paired data (p <0.001)
`showed that for the lesions on the resveratrol-treated side of the
`face the median of the differences in GAGS scores was negative,
`in contrast to what was observed on the vehicle-treated side of
`the face. Based on this result, it could be argued that the re-
`duction in the degree of acne severity on the treated side of the
`face was statistically significant (figures 2 and 3).
`The analysis of cyanoacrylate follicular biopsies showed a
`66.7% mean decrease from baseline in the total area and a de-
`
`The etiology of acne is not yet fully clarified but it is widely
`accepted that its pathogenesis is multifactorial, with abnormal
`follicular differentiation and increased cornification, enhanced
`sebaceous gland activity and hyperseborrhea, and bacterial
`hypercolonization, as well as inflammation and immunologic
`host reactions being the major contributors.
`New research into acne pathogenesis has identified several
`novel pharmacologic targets to interrupt the inflammatory
`
`Discussion
`
`© 2011 Adis Data Information BV All rights reserved
`
`Am J Clin Dermato12011; 12 (2)
`
`5 of 9
`
`

`

`138
`
`a
`
`Fabbrocini et al.
`
`Resveratrol is a natural compound produced by some
`spermatophytes, such as grapes and other plants, and is present
`at concentrations of up to 100 gmol/L in red wines and at much
`lower concentrations in white wines. It is reported to have
`cardiovascular-protective, cancer-chemopreventive, antioxidant,
`and anti-inflammatory properties.I23,241
`The keratinocytic hyperproliferation process, which is the
`basis of the follicular obstruction in acne, appears to be inhibited
`by resveratrol. In fact, even at submicromolar concentrations,
`resveratrol inhibits the proliferation of normal human keratino-
`cytes in vitro and at higher concentrations (40 100gmol/L)
`is cytotoxic to these cells.I2sl Our previous studies of HaCaT cells
`(a model for skin keratinocytes) indicated that resveratrol
`
`Fig. 2. A patient (no. 1) before (a) and after (b) treatment with resveratrol-
`containing gel.
`
`acne process. Indeed, some anti-inflammatory activity ob-
`served with the use of oral antibacterials may relate to their
`action in the inflammatory cascade.I211 Based on the patho-
`physiology of the disease, researchers have targeted therapy to
`try to suppress hyperseborrhea and the inflammatory response,
`and also inhibit keratinocytes and P. aches proliferation. From
`this point of view, resveratrol seems to be an interesting mole-
`cule because it is able to interfere with the hyperproliferation
`of keratinocytes, the inflammatory response, and P. aches
`growth.[221
`
`Fig. 3. A patient (no. 3) before (a) and after (b) treatment with resveratrol-
`containing gel.
`
`© 2011 Adis Data Information BV All rights reserved
`
`Am J Clin Dermato12011; 12 (2)
`
`6 of 9
`
`

`

`Resveratrol-Containing Gel for Acne Vulgaris
`
`139
`
`Table III. The average area of microcomedones before and after treatment with resveratrol and vehicle gels
`
`Patient no.
`
`Resveratrol-treated side
`
`Vehicle-treated side
`
`before treatment
`
`after treatment
`
`change (%)
`
`before treatment
`
`after treatment
`
`change (%)
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`0.022
`
`0.016
`
`0.016
`
`0.024
`
`0.017
`
`0.022
`
`0.024
`
`0.025
`
`0.020
`
`0.024
`
`0.015
`
`0
`
`0.012
`
`0
`
`0.013
`
`0
`
`0.01
`
`0.01
`
`0
`
`0
`
`-32
`
`-100
`
`-25
`
`-100
`
`-24
`
`-100
`
`-96
`
`-60
`
`-100
`
`-100
`
`0.025
`
`0.010
`
`0.019
`
`0.021
`
`0.021
`
`0.014
`
`0.023
`
`0.021
`
`0.022
`
`0.025
`
`0.020
`
`0.010
`
`0.016
`
`0.025
`
`0.018
`
`0.011
`
`0.018
`
`0.022
`
`0.019
`
`0.022
`
`0.023
`
`-20
`
`0
`
`-16
`
`+19
`
`-14
`
`-21
`
`-22
`
`+5
`
`-14
`
`-12
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`Mean
`
`0.021
`
`0.022
`
`0.018
`
`0.018
`
`0.024
`
`0.022
`
`0.018
`
`0.020
`
`0.022
`
`0.017
`
`0.021
`
`0.005
`
`0.009
`
`0.006
`
`0.005
`
`0.003
`
`0.012
`
`0.008
`
`0.010
`
`0.009
`
`0.010
`
`0.007
`
`-76
`
`-59
`
`-64
`
`-72
`
`-88
`
`-45
`
`-56
`
`-50
`
`-59
`
`-41
`
`-66.7
`
`0.025
`
`0.024
`
`0.021
`
`0.020
`
`0.024
`
`0.025
`
`0.017
`
`0.018
`
`0.021
`
`0.016
`
`0.021
`
`0.023
`
`0.020
`
`0.018
`
`0.022
`
`0.023
`
`0.015
`
`0.015
`
`0.018
`
`0.014
`
`0.019
`
`-8
`
`-4
`
`-5
`
`-10
`
`-8
`
`-8
`
`-12
`
`-17
`
`-14
`
`-13
`
`-9.7
`
`sveratrolcould be considered a potentially interesting molecule
`acts on an adaptive protein, p66, which at elevated doses
`leads to apoptosis, while in physiologic conditions promotes
`for acne treatment.
`In this study, we applied resveratrol in a carboxymethyl-
`senescence.I261
`cellulose-based gel. We demonstrated that resveratrol was stable
`Furthermore, resveratrol interferes with inflammation be-
`in its trans-form upon storage of the gel at 4°C for the time neces-
`cause it regulates numerous intracellular signaling cascades
`sary for the study. No preservative was added to the formulation
`converging with the activation of nuclear factor-KB and acti-
`in order to avoid interference with the activity of resveratrol.
`vator protein-1, which act independently or in combination to
`Future studies will be focused on the development ofa resveratrol-
`control the expression of target genes, such as TNF~, IL- 1 [3,
`and metalloproteinases.[27] In vivo experiments in mice showed
`containing gel suitable for long-term storage. Moreover, the use of
`nanotechnologies to improve the resveratrol penetration into the
`a reduction in TNF~ in splenic cells after treatment with re-
`skin will be investigated. Therefore, further studies are planned to
`sveratrol from 2 to 4 weeks, blocking the early stage of the
`inflammatory process.I281 It has been shown that resveratrol is
`evaluate new formulations, with the aim of developing a com-
`active against several bacteria, including Neisseria gonorrhoeae, mercial preparation.
`Neisseria rneningitidis,[29] Helicobacter pylori,[3°] Staphylococcus
`aureus, Enterococcus Jaecalis, Pseudomonas aeruginosa,[311 and
`Proteus mirabilis.[321 Recently, it has been reported that resver-
`atrol inhibits P. acnes replication in vitro at the lowest con-
`centration tested (50 mg/L) and is bactericidal at the highest
`concentration tested (200 mg/L).I331
`Because of its anti-inflammatoryproperties, its antiproliferative
`effects, and its ability to inhibit P. acnes, we believed that re-
`
`At the end of the study, all patients had a visible clinical
`improvement on the resveratrol-treated side of the face, in-
`cluding a remarkable decrease in inflammation and pustular
`lesions. This clinical improvement was well documented by
`digital photographs. Our results indicate a clinically relevant
`
`Conclusion
`
`© 2011 Adis Data Information BV All rights reserved
`
`Am J Clin Dermato12011; 12 (2)
`
`7 of 9
`
`

`

`140
`
`Fabbrocini et al.
`
`and statistically significant decrease of microcomedones and
`macrocomedones in facial areas treated with the gel for-
`mulation containing resveratrol. The treatment was well tol-
`erated, with no adverse effects reported on the resveratrol- or
`vehicle-treated sides of the face. All patients were satisfied with
`the treatment in terms of compliance, smell, texture, results,
`and quality of life. Our study provides only preliminary evi-
`dence for an alternative treatment for patients affected by acne
`vulgaris but it should be considered a valid starting point for
`further research into the effectiveness ofresveratrol at different
`concentrations, in innovative formulations, in larger groups of
`patients, and for more widespread use on the body.
`
`a
`
`’~
`,
`
`i
`
`°’
`
`~
`
`~
`
`l
`
`ll~
`.~
`
`t
`
`.,
`
`"
`
`P
`
`0/ ~
`11,
`
`)
`
`’
`
`.
`
`~
`
`~,
`i
`
`~
`
`’
`!
`
`~
`
`’~
`
`I~
`
`.~
`,
`
`!
`
`b
`
`,
`
`\
`: t!
`
`t
`
`"
`
`4
`
`|
`
`,"
`
`~
`
`~.
`!
`
`0
`
`,o. ; ’
`
`b
`

`
`," [
`
`r
`
`,,
`
`.p,,’
`. t ’ O
`
`,.
`
`A
`
`Fig. 5. A follicular biopsy before (a) and after (b) treatment with resveratrol-
`containing gel (patient no. 3).
`
`*O
`
`Acknowledgments
`
`j
`
`~.
`
`""
`
`!
`
`’~
`
`1~"i
`
`This study was achieved thanks to the contribution of the "Assessorato
`all’agricoltura e alle attivitfi Produttive della Regione Campania." The
`authors have no conflicts of interest that are directly relevant to the content
`of this study.
`
`Fig. 4. A follicular biopsy before (a) and after (b) treatment with resveratrol-
`containing gel (patient no. 1).
`
`2. Morohashi M, Toyoda M. Pathogenesis ofacne: medical electron microscopy.
`Med Electron Microsc 2001; 34 (1): 29-40
`
`© 2011 Adis Data Information BV All rights reserved
`
`Am J Clin Dermato12011; 12 (2)
`
`References
`1. Goodman G. Acne and acne scarring: the case for active and early intervention.
`Aust Fam Physician 2006; 35:503-4
`
`8 of 9
`
`

`

`Resveratrol-Containing Gel for Acne Vulgaris
`
`141
`
`3. Peck G, Olsen T, Yoder F, et al. Prolonged remissions of cystic and conglobate
`acne with 13-cis-retinoic acid. N Engl J Med 1979; 300:329-33
`
`4. Strauss J, Rapini R, Shalita A, et al. Isotretinoin therapy for acne: results of a
`multicenter dose-response study. J Am Acad Dermatol 1984; 10:490-6
`
`5. Newman MD, Bowe WP, Heughebaert C, et al. Therapeutic considerations for
`severe nodular acne. Am J Clin Dermatol 2011; 12:7-14
`
`6. Ganceviciene R, Zouboulis CC. Isotretinoin: state of the art treatment for acne
`vulgaris. J Dtsch Dermatol Ges 2010; 8:47-59
`
`7. Wysowski D, Pitts M, Beitz J. Depression and suicide in patients treated with
`isotretinoin [letter]. N Engl J Med 2001; 344:460
`
`8. Jick S, Kremers H, Vasilakis-Scaramozza C. Isotretinoin use and risk of de-
`pression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol
`2000; 136:1231-6
`
`20. Chen X, He H, Wang G, et al. Stereospecific determination of cis- and trans-
`resveratrol in rat plasma by HPLC: application to pharmacokinetic studies.
`Biomed Chromatogr 2007 Mar; 21 (3): 257-65
`
`21. Wyckoff TJ, Raetz CR, Jackman JE. Antibacterial and anti-inflammatory
`agents that target endotoxin. Trends Microbiol 1998; 6:154-9
`
`22. Subbaramaiah K, Chung WJ, Michaluart P, et al. Resveratrol inhibits cyclo-
`oxygenase-2 transcription and activity in phorbol ester-treated human
`mammary epithelial cells. J Biol Chem 1998; 273:21875-82
`
`23. Donnelly LE, Newton R, Kennedy GE, et al. Anti-inflammatory effects of
`resveratrol in lung epithelial cells: molecular mechanisms. Am J Physio Lung
`Cell Mol Physiol 2004; 287:L774-83
`
`24. Lawrence M, Szewczuk, Luca Forti, et al. Stivala resveratrol is a peroxidase-
`mediated inactivator of COX-1 but not COX-2 a mechanistic approach to the
`design of COX-1 selective agen

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket